| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Suavissimoside R1 targets neuroprotective pathways involved in Parkinson's disease and other neurodegenerative conditions. Its neuroprotective effects may involve the modulation of oxidative stress, inflammation, and mitochondrial function in neurons. By protecting neurons from damage, the compound may slow or prevent the progression of neurodegenerative diseases. However, the specific molecular targets of Suavissimoside R1 have not been fully elucidated.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Suavissimoside R1 possesses potent neuroprotective activity. The compound protects neurons from damage in models of Parkinson's disease. Its neuroprotective effects are assessed in neuronal cell lines or primary neurons exposed to neurotoxic insults (e.g., MPTP, 6-OHDA, rotenone). Cell viability is measured using MTT or similar assays. Oxidative stress markers and mitochondrial function are assessed to elucidate the mechanism of neuroprotection.
|
| ln Vivo |
In vivo activity of Suavissimoside R1 has been evaluated in animal models of Parkinson's disease. The compound has the potential to treat Parkinson's disease, suggesting efficacy in animal models of this condition. However, detailed in vivo efficacy data, including specific animal models and dosing regimens, are not extensively reported in the available literature. The compound is primarily used as a research tool for studying neuroprotection.
|
| Enzyme Assay |
In vitro assays for Suavissimoside R1 involve measuring its neuroprotective activity. Neuronal cell lines (e.g., SH-SY5Y, PC12) or primary neurons are treated with the compound and exposed to neurotoxic insults (e.g., MPTP, 6-OHDA, rotenone, H2O2). Cell viability is assessed using MTT, CCK-8, or LDH release assays. Oxidative stress is measured using ROS detection probes (e.g., DCFH-DA). Mitochondrial function is assessed by measuring mitochondrial membrane potential (JC-1) and ATP levels.
|
| Cell Assay |
Cellular assays for Suavissimoside R1 are conducted to evaluate its neuroprotective effects. Neuronal cells are treated with varying concentrations of the compound for 1-24 hours prior to exposure to neurotoxic insults. Cell viability is assessed using MTT or similar assays. Apoptosis is evaluated by Annexin V/PI staining, caspase-3/7 activity, or TUNEL assays. Oxidative stress markers (ROS, MDA) and antioxidant enzyme activities (SOD, CAT) are measured. Mitochondrial function is assessed using JC-1 staining and ATP measurement.
|
| Animal Protocol |
In vivo animal studies with Suavissimoside R1 are conducted in models of Parkinson's disease. Animal models such as MPTP-treated mice or 6-OHDA-lesioned rats are used. Animals are treated with the compound via oral or intraperitoneal administration at various doses. Neurobehavioral tests (e.g., rotarod, open field) are performed to assess motor function. Brain tissues are collected for histological analysis (e.g., tyrosine hydroxylase staining), oxidative stress markers, and inflammatory cytokine measurement.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Suavissimoside R1 have not been extensively characterized. The compound has a molecular weight of 680.82 and a molecular formula of C3₆H₅₆O12. The compound is a triterpenoid with moderate lipophilicity. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported. The compound is typically stored at 2-8degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Suavissimoside R1 are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for neuroprotection studies. The compound is derived from Rubus parvifolius, a plant with a generally favorable safety profile. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Suavissimoside R1 has been reported in Rubus ellipticus var. obcordatus, Trachelospermum asiaticum, and other organisms for which data are available.
Suavissimoside R1 is a triterpenoid from Rubus parvifolius with potent neuroprotective activity and potential for treating Parkinson's disease. The compound is not an FDA-approved drug and has no clinical indications. It is available in high purity and is typically stored at 2-8degC. |
| Molecular Formula |
C36H56O12
|
|---|---|
| Molecular Weight |
680.822652816772
|
| Exact Mass |
680.377
|
| CAS # |
95645-51-5
|
| PubChem CID |
21626352
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
48
|
| Complexity |
1350
|
| Defined Atom Stereocenter Count |
17
|
| SMILES |
C([C@]12CC[C@@H](C)[C@](O)(C)[C@H]1C1=CC[C@@H]3[C@]4(C[C@@H](O)[C@H](O)[C@@](C)(C(=O)O)[C@@H]4CC[C@@]3(C)[C@@]1(CC2)C)C)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
|
| InChi Key |
YXSQSVWHKZZWDD-FPLSKCGGSA-N
|
| InChi Code |
InChI=1S/C36H56O12/c1-17-9-12-36(30(45)48-28-25(41)24(40)23(39)20(16-37)47-28)14-13-32(3)18(26(36)35(17,6)46)7-8-21-31(2)15-19(38)27(42)34(5,29(43)44)22(31)10-11-33(21,32)4/h7,17,19-28,37-42,46H,8-16H2,1-6H3,(H,43,44)/t17-,19-,20-,21-,22-,23-,24+,25-,26-,27+,28+,31-,32-,33-,34+,35-,36+/m1/s1
|
| Chemical Name |
(2R,3R,4S,4aR,6aR,6bS,8aS,11R,12R,12aS,14aR,14bR)-2,3,12-trihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4688 mL | 7.3441 mL | 14.6882 mL | |
| 5 mM | 0.2938 mL | 1.4688 mL | 2.9376 mL | |
| 10 mM | 0.1469 mL | 0.7344 mL | 1.4688 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
